| scholarly article | Q13442814 |
| P356 | DOI | 10.1159/000335472 |
| P698 | PubMed publication ID | 22269894 |
| P50 | author | Ann-Lii Cheng | Q38639483 |
| P2093 | author name string | Andrew X Zhu | |
| Ying-Chun Shen | |||
| P2860 | cites work | Signaling via fibroblast growth factor receptor-1 is dependent on extracellular matrix in capillary endothelial cell differentiation | Q40964458 |
| E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models | Q42816147 | ||
| The Significance of Fibroblast Growth Factor Receptor 2 Expression in Differentiation of Hepatocellular Carcinoma | Q43451322 | ||
| Angiogenesis soluble factors as hepatocellular carcinoma noninvasive markers for monitoring hepatitis C virus cirrhotic patients awaiting liver transplantation. | Q44934094 | ||
| Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention | Q45254446 | ||
| A phase I pharmacokinetic and pharmacodynamic study of TKI258, an oral, multitargeted receptor tyrosine kinase inhibitor in patients with advanced solid tumors | Q46669648 | ||
| Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. | Q53331692 | ||
| Plasma level of basic fibroblast growth factor increases with progression of chronic liver disease. | Q53446253 | ||
| Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. | Q53578148 | ||
| Altered expression of vascular endothelial growth factor, fibroblast growth factor-2 and endostatin in patients with hepatocellular carcinoma. | Q54669173 | ||
| A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carcinoma. | Q54681050 | ||
| Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family | Q24676527 | ||
| Increased carbon tetrachloride-induced liver injury and fibrosis in FGFR4-deficient mice | Q24684986 | ||
| A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice | Q24685118 | ||
| Insights into the Pathobiology of Hepatitis C Virus-Associated Cirrhosis | Q27478238 | ||
| Management of hepatocellular carcinoma: An update | Q27860530 | ||
| Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets | Q28303698 | ||
| Different thresholds of fibroblast growth factors pattern the ventral foregut into liver and lung | Q28591023 | ||
| Liver fibrosis | Q29547449 | ||
| Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors | Q29615445 | ||
| Fibroblast growth factor signalling: from development to cancer | Q29616827 | ||
| Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer | Q33397708 | ||
| FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation | Q33648263 | ||
| Phase I study of the angiogenesis inhibitor BIBF 1120 in patients with advanced solid tumors. | Q34089525 | ||
| FGF receptors 1 and 2 control chemically induced injury and compound detoxification in regenerating livers of mice | Q34172882 | ||
| Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis | Q34223462 | ||
| Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening | Q34701235 | ||
| Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma | Q34842280 | ||
| A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors | Q35116704 | ||
| Role of Fibroblast Growth Factor Type 1 and 2 in Carbon Tetrachloride-Induced Hepatic Injury and Fibrogenesis | Q35792203 | ||
| Over-expression of fibroblast growth factor receptor 3 in human hepatocellular carcinoma | Q36213899 | ||
| Hepatocellular carcinoma. A worldwide problem and the major risk factors | Q36401904 | ||
| Large induction of keratinocyte growth factor expression in the dermis during wound healing | Q37126541 | ||
| Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. | Q37157400 | ||
| Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma | Q37847011 | ||
| Differential expression of the fibroblast growth factor receptor (FGFR) multigene family in normal human adult tissues | Q38474392 | ||
| Up-regulation of the fibroblast growth factor 8 subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. | Q39592731 | ||
| Antitumor activity of BIBF 1120, a triple angiokinase inhibitor, and use of VEGFR2+pTyr+ peripheral blood leukocytes as a pharmacodynamic biomarker in vivo | Q39623814 | ||
| The antiangiogenic activity in xenograft models of brivanib, a dual inhibitor of vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 kinases. | Q39747642 | ||
| P433 | issue | 5-6 | |
| P304 | page(s) | 372-380 | |
| P577 | publication date | 2011-01-01 | |
| P1433 | published in | Oncology | Q2016300 |
| P1476 | title | Targeting fibroblast growth factor receptor signaling in hepatocellular carcinoma | |
| P478 | volume | 81 |
| Q24658608 | (125)I-labeled anti-bFGF monoclonal antibody inhibits growth of hepatocellular carcinoma |
| Q33440392 | A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma. |
| Q44607425 | A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma |
| Q54976445 | A novel association between core mutations in hepatitis B virus genotype F1b and hepatocellular carcinoma in Alaskan Native People. |
| Q47890330 | A possible role of microRNAs as predictive markers for the recurrence of hepatocellular carcinoma after liver transplantation |
| Q89250918 | Angiogenesis and Hepatic Fibrosis: Western and Chinese Medicine Therapies on the Road |
| Q95276807 | Angiogenesis in Hepatocellular Carcinoma; Pathophysiology, Targeted Therapy, and Role of Imaging |
| Q34525925 | Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors |
| Q38923517 | Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma |
| Q38974755 | Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma. |
| Q92980089 | Fibroblast growth factor signaling in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Paving the way to hepatocellular carcinoma |
| Q98288232 | Hepatic microenvironment underlies fibrosis in chronic hepatitis B patients |
| Q26771518 | Hepatoprotective and Anti-fibrotic Agents: It's Time to Take the Next Step |
| Q58731797 | Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression |
| Q35922102 | Inhibition of protein kinase C by isojacareubin suppresses hepatocellular carcinoma metastasis and induces apoptosis in vitro and in vivo |
| Q33751398 | Is fibroblast growth factor receptor 4 a suitable target of cancer therapy? |
| Q35913384 | Liver cancer oncogenomics: opportunities and dilemmas for clinical applications |
| Q38197503 | Orchestration of hepatocellular carcinoma development by diverse liver cancer stem cells |
| Q41166121 | Polymorphisms of FGFR1 in HBV-related hepatocellular carcinoma |
| Q37031712 | Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives |
| Q47266310 | Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma |
| Q33275125 | The FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survival |
Search more.